[2]Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021 Aug;22(8):1151-1161. [3]Xi E Hu, Ping Yang, Songhao...
[1]Guarneri V, Barbieri E, Dieci MV, et al. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. Cancer Treat Rev. 2010 Nov;36 Suppl 3:S62-6. [2]Denkert C, Seither F, Schneeweiss A, et al....
[8] Spring LM, Barlow WE, Bardia A, et al. Impact of HER2 low status on clinical outcomes in participants with 1-3 positive lymph nodes, HR+/HER2- breast cancer with recurrence score [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Anton...
首先它是HER2-Positive，就是HER-2还是阳性的，就是三个加号，或者说是两个加号经过FISH验证以后是阳性。注意两个加号不能直接用，我再强调一遍，必须要做FISH然后验证它是阳性才可以，HER2-Positive，然后推荐的这个方案，有点尴尬，它用了帕妥珠单抗，曲妥珠单抗和多西他赛，这是推荐度最高的category1。这个是二级...
[3]Von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019;380(7):617-628.[4]Müller V, Bachelot T, Curigliano G, et al. Expert consensus on the prevention of brain metastases in patients with HER2-...
DG-03 Part 2 (dose expansion; NCT04379596) enrolled pts with 1L HER2+ (immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization-positive by local testing) esophageal/gastric/GEJA globally, irrespective of PD-L1 sta...
2022 Mar;163:35-43.[2] Shanu Modi et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. July 7, 2022 .N Engl J Med 2022; 387:9-20DOI: 10.1056/NEJMoa2203690[3] RC48-ADC， a HER2-targeting antibody-drug conjugate， in patients with HER2-positive and ...
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade Article Open access 20 January 2020 HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway Article Open access 18 November 2021 HER2-targeted therapies beyond breast cancer — an ...
6.Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742...
图14. DEBBRAH研究中队列1-3的疗效结果 TUXEDO-1研究是一项前瞻性、单中心、单臂的II期临床试验,共纳入15例HER2阳性乳腺癌活动性脑转移患者(脑转移新诊断尚未治疗或脑转移经局部治疗后进展、经曲妥珠单抗和帕妥珠单抗治疗后无立即局部治疗条件),研究结果曾相继亮相于2021年和2022年ESMO大会,并且期间(2022...